New JCA regulation and early access program

We are excited to announce an upcoming educational event in the Parkhotel Zug, where we will focus on the latest developments in the new EU HTA process Joint Clinical Assessments and European early access programs with a focus on the French Reimbursed Early Access Programs.

Agenda highlights:

The JCA revolution: what you need to know for a successful market access

The JCA countdown - Essential insights and the latest developments before January 2025
JCA process integration - Synchronizing with EMA timelines. Why early action matters
Optimizing your JCA strategy - PICO anticipation, key milestones, and lead time considerations
JCA dossier deep dive: Understanding the structure and data requirements
Preparing your team for JCA success - Building the right capabilities and resources
Impact on market access - Will JCA revolutionize or supplement national HTA processes?
What’s next? - Preparing for future JCA implementation phases

Unlocking early market access in Europe: opportunities and case studies

Overview of European early access programs - Pathways to accelerated market entry
Comparing options - Reimbursed early access vs compassionate use
Leveraging the reimbursed French early access programs - Commercialization with free pricing
Success stories - Real-world case studies of early access
Beyond medicines - Exploring early access opportunities for medical devices and diagnostics

The event will feature a 60-minute presentation followed by a meet-and-greet with cocktails, providing an excellent opportunity for networking and discussion. Don't miss out on this chance to network with fellow professionals and expand your knowledge.